The University of Houston College of Pharmacy joins the RAPID Alliance MÃ©dicaments 360 study with the goal of transforming the way drugs and vaccines are delivered in the United States from 2022 to 2031. The RAPIDE Alliance is a multi-stakeholder research consortium founded in the University of Louisville Center for Healthcare Organization Transformation (CHOT), a research center funded by the National Science Foundation.
The college will help lead an effort on the bridge to co-create the “RAPID Alliance Medicines 360 framework 2022-2031 â, a set of transformation strategies and a priority research program at the national level to optimize the use of drugs, vaccinations and other therapies from 2022 to 2031.
This project builds on a 2020 research study, conducted by UofL researchers during the COVID-19 pandemic, which identified strategic opportunities to improve the health and well-being of tens of millions of people while reducing US spending on hospitalizations and emergency department and doctor visits. up to $ 528 billion.
The University of Houston College of Pharmacy will help this effort by supporting research and action in areas, including state-level strategies for Texas. In addition, UHCOP will help support sections of special studies on topics such as medication adherence, hard evidence, prescription drug abuse, geriatric care and chronic disease management.
âTechnological advancements and the rise of pharmacogenomics and personalized medicine are leading to a new golden age in the discovery, development and delivery of safe and effective drug therapies, but we continue to struggle with challenges of long-standing in areas such as health disparities, drug adherence and abuse and, more recently, reluctance and misinformation about vaccines, âsaid the Dean of the College of pharmacy F. Lamar Pritchard, Professor and Humana Endowed Dean Chair in Pharmacy. âOur college is proud to join this large-scale initiative that works to find evidence-based solutions to help create healthier communities nationwide.â
Universities participating in the RAPID Alliance and its Medications 360 study include American University of Health Sciences, Belmont University, Binghamton University, California Northstate University, Chapman University, Ferris State University, Howard University, Lipscomb University, Loma Linda University, Long Island University, Marshall University, Medical College of Wisconsin, Mercer University, North Dakota State University, Oregon Heath & Science University, Oregon State University, South Dakota State University, Sullivan University, Temple University, University of Arkansas for Medical Sciences, University of Cincinnati, University of Colorado, University of Georgia, University of Hawaii Hilo, University of Houston, University of Kentucky, University of Louisville, University of Michigan, University of Mississippi, University of Nebraska Medical Center, University of Nevada Reno, University of Pittsburgh, University of Rhode Island, University of Carol South ine, University of Tennessee, Washington State University, Wayne State University, and Western University of Health Sciences.
âWe are delighted to see this multi-university research consortium grow,â said Lucinda Maine, Executive Director of the American Association of Colleges of Pharmacy (AACP), a founding member of the RAPID Alliance Practice Council. “We believe national and state research-based strategies are critical to optimizing drug use for American populations over the next decade.”
The consortium plans to add up to 30 additional universities in the coming months to support the effort.
Want to join the strategic planning effort? Leading healthcare companies, associations, government agencies, foundations, technology providers and other stakeholders at national and state levels are invited and encouraged to involve one or more strategic leaders in the strategic planning process.